Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 유대현 | - |
dc.date.accessioned | 2019-11-20T06:45:46Z | - |
dc.date.available | 2019-11-20T06:45:46Z | - |
dc.date.issued | 2017-02 | - |
dc.identifier.citation | ANNALS OF THE RHEUMATIC DISEASES, v. 76, no. 2, page. 355-363 | en_US |
dc.identifier.issn | 0003-4967 | - |
dc.identifier.issn | 1468-2060 | - |
dc.identifier.uri | https://ard.bmj.com/content/76/2/355 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/112568 | - |
dc.description.abstract | Objectives To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in patients with rheumatoid arthritis (RA) for an additional six infusions.Methods This open-label extension study recruited patients with RA who had completed the 54-week, randomised, parallel-group study comparing CT-P13 with RP (PLANETRA; NCT01217086). CT-P13 (3 mg/kg) was administered intravenously every 8 weeks from weeks 62 to 102. All patients received concomitant methotrexate. Endpoints included American College of Rheumatology 20% (ACR20) response, ACR50, ACR70, immunogenicity and safety. Data were analysed for patients who received CT-P13 for 102 weeks (maintenance group) and for those who received RP for 54 weeks and then switched to CT-P13 (switch group).Results Overall, 302 of 455 patients who completed the PLANETRA study enrolled into the extension. Of these, 158 had received CT-P13 (maintenance group) and 144 RP (switch group). Response rates at week 102 for maintenance versus switch groups, respectively, were 71.7% vs 71.8% for ACR20, 48.0% vs 51.4% for ACR50 and 24.3% vs 26.1 % for ACR70. The proportion of patients with antidrug antibodies was comparable between groups (week 102: 40.3% vs 44.8%, respectively). Treatment-emergent adverse events occurred in similar proportions of patients in the two groups during the extension study (53.5% and 53.8%, respectively).Conclusions Comparable efficacy and tolerability were observed in patients who switched from RP to its biosimilar CT-P13 for an additional year and in those who had long-term CT-P13 treatment for 2 years. | en_US |
dc.description.sponsorship | This study was funded by CELLTRION Inc. The sponsor participated in study design, in the collection, analysis and interpretation of study data and in reviewing drafts of the manuscript. The final decision to submit the manuscript was made by the authors. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | BMJ PUBLISHING GROUP | en_US |
dc.subject | LONG-TERM EFFICACY | en_US |
dc.subject | MODIFYING ANTIRHEUMATIC DRUGS | en_US |
dc.subject | ALPHA MONOCLONAL-ANTIBODY | en_US |
dc.subject | COLONY-STIMULATING FACTOR | en_US |
dc.subject | CHRONIC KIDNEY-DISEASE | en_US |
dc.subject | EPOETIN-ALPHA | en_US |
dc.subject | ANKYLOSING-SPONDYLITIS | en_US |
dc.subject | RENAL ANEMIA | en_US |
dc.subject | DOUBLE-BLIND | en_US |
dc.subject | THERAPEUTIC EQUIVALENCE | en_US |
dc.title | Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study | en_US |
dc.type | Article | en_US |
dc.relation.no | 2 | - |
dc.relation.volume | 76 | - |
dc.identifier.doi | 10.1136/annrheumdis-2015-208786 | - |
dc.relation.page | 355-363 | - |
dc.relation.journal | ANNALS OF THE RHEUMATIC DISEASES | - |
dc.contributor.googleauthor | Yoo, Dae Hyun | - |
dc.contributor.googleauthor | Prodanovic, Nenad | - |
dc.contributor.googleauthor | Jaworski, Janusz | - |
dc.contributor.googleauthor | Miranda, Pedro | - |
dc.contributor.googleauthor | Ramiterre, Edgar | - |
dc.contributor.googleauthor | Lanzon, Allan | - |
dc.contributor.googleauthor | Baranauskaite, Asta | - |
dc.contributor.googleauthor | Wiland, Piotr | - |
dc.contributor.googleauthor | Abud-Mendoza, Carlos | - |
dc.contributor.googleauthor | Oparanov, Boycho | - |
dc.relation.code | 2017001393 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | dhyoo | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.